183 related articles for article (PubMed ID: 24128299)
21. Anticipatory Positive Urine Tests for Bladder Cancer.
Gopalakrishna A; Fantony JJ; Longo TA; Owusu R; Foo WC; Dash R; Denton BT; Inman BA
Ann Surg Oncol; 2017 Jun; 24(6):1747-1753. PubMed ID: 28074325
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer.
Trenti E; D'Elia C; Mian C; Schwienbacher C; Hanspeter E; Pycha A; Kafka M; Degener S; Danuser H; Roth S; Pycha A
Cancer Cytopathol; 2019 Jul; 127(7):465-469. PubMed ID: 31154670
[TBL] [Abstract][Full Text] [Related]
23. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings.
Yoder BJ; Skacel M; Hedgepeth R; Babineau D; Ulchaker JC; Liou LS; Brainard JA; Biscotti CV; Jones JS; Tubbs RR
Am J Clin Pathol; 2007 Feb; 127(2):295-301. PubMed ID: 17210520
[TBL] [Abstract][Full Text] [Related]
24. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer.
Zellweger T; Benz G; Cathomas G; Mihatsch MJ; Sulser T; Gasser TC; Bubendorf L
Int J Cancer; 2006 Oct; 119(7):1660-5. PubMed ID: 16646074
[TBL] [Abstract][Full Text] [Related]
25. UroVysion® multiprobe FISH in the triage of equivocal urinary cytology cases.
Bubendorf L; Piaton E
Ann Pathol; 2012 Dec; 32(6):e52-6, 438-43. PubMed ID: 23244486
[TBL] [Abstract][Full Text] [Related]
26. Clinical evaluation of two consecutive UroVysion fluorescence in situ hybridization tests to detect intravesical recurrence of bladder cancer: a prospective blinded comparative study in Japan.
Kojima T; Nishiyama H; Ozono S; Hinotsu S; Keino N; Yamaguchi A; Sakai H; Enomoto Y; Horie S; Fujimoto K; Matsuyama H; Okamura T; Kanimoto Y; Oya M; Nonomura N; Naito S; Akaza H
Int J Clin Oncol; 2018 Dec; 23(6):1140-1147. PubMed ID: 29971622
[TBL] [Abstract][Full Text] [Related]
27. Stepwise application of urine markers to detect tumor recurrence in patients undergoing surveillance for non-muscle-invasive bladder cancer.
Todenhöfer T; Hennenlotter J; Esser M; Mohrhardt S; Aufderklamm S; Böttge J; Rausch S; Mischinger J; Bier S; Gakis G; Kuehs U; Stenzl A; Schwentner C
Dis Markers; 2014; 2014():973406. PubMed ID: 25587206
[TBL] [Abstract][Full Text] [Related]
28. Prospective Validation of Clinical Usefulness of a Novel mRNA-based Urine Test (Xpert® Bladder Cancer Monitor) for surveillance in Non Muscle Invasive Bladder Cancer.
Elsawy AA; Awadalla A; Elsayed A; Abdullateef M; Abol-Enein H
Urol Oncol; 2021 Jan; 39(1):77.e9-77.e16. PubMed ID: 32800441
[TBL] [Abstract][Full Text] [Related]
29. Risk for intravesical recurrence of bladder cancer stratified by the results on two consecutive UroVysion fluorescence in situ hybridization tests: a prospective follow-up study in Japan.
Ikeda A; Kojima T; Kawai K; Hinotsu S; Keino N; Shiga K; Miyake H; Miyata Y; Enomoto Y; Shimizu F; Anai S; Matsuyama H; Suzuki C; Kanimoto Y; Shigeta K; Naito S; Akaza H; Nishiyama H
Int J Clin Oncol; 2020 Jun; 25(6):1163-1169. PubMed ID: 32125546
[TBL] [Abstract][Full Text] [Related]
30. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria.
Sarosdy MF; Kahn PR; Ziffer MD; Love WR; Barkin J; Abara EO; Jansz K; Bridge JA; Johansson SL; Persons DL; Gibson JS
J Urol; 2006 Jul; 176(1):44-7. PubMed ID: 16753364
[TBL] [Abstract][Full Text] [Related]
31. Assessing treatment response after intravesical bacillus Calmette-Guerin induction cycle: are routine bladder biopsies necessary?
Calò B; Sanguedolce F; Falagario UG; Chirico M; Fortunato F; Carvalho-Diaz E; Busetto GM; Bettocchi C; Carrieri G; Cormio L
World J Urol; 2021 Oct; 39(10):3815-3821. PubMed ID: 33830306
[TBL] [Abstract][Full Text] [Related]
32. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
[TBL] [Abstract][Full Text] [Related]
33. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy.
Savic S; Zlobec I; Thalmann GN; Engeler D; Schmauss M; Lehmann K; Mattarelli G; Eichenberger T; Dalquen P; Spieler P; Schoenegg R; Gasser TC; Sulser T; Forster T; Zellweger T; Casella R; Bubendorf L
Int J Cancer; 2009 Jun; 124(12):2899-904. PubMed ID: 19230026
[TBL] [Abstract][Full Text] [Related]
34. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.
Valenberg FJPV; Hiar AM; Wallace E; Bridge JA; Mayne DJ; Beqaj S; Sexton WJ; Lotan Y; Weizer AZ; Jansz GK; Stenzl A; Danella JF; Shepard B; Cline KJ; Williams MB; Montgomery S; David RD; Harris R; Klein EW; Bradford TJ; Wolk FN; Westenfelder KR; Trainer AF; Richardson TA; Egerdie RB; Goldfarb B; Zadra JA; Ge S; Zhao S; Simon IM; Campbell SA; Rhees B; Bates MP; Higuchi RG; Witjes JA
Eur Urol; 2019 May; 75(5):853-860. PubMed ID: 30553612
[TBL] [Abstract][Full Text] [Related]
35. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
36. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
[TBL] [Abstract][Full Text] [Related]
37. [Can the combination of bladder ultrasonography and urinary cytodiagnosis replace cystoscopy in the diagnosis and follow-up of tumors of the bladder?].
Cariou G; Maaraoui N; Cortesse A
Prog Urol; 1997 Feb; 7(1):51-5. PubMed ID: 9116739
[TBL] [Abstract][Full Text] [Related]
38. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology.
Daniely M; Rona R; Kaplan T; Olsfanger S; Elboim L; Freiberger A; Lew S; Leibovitch I
Cancer; 2007 Dec; 111(6):517-24. PubMed ID: 17963263
[TBL] [Abstract][Full Text] [Related]
39. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer.
Varella-Garcia M; Akduman B; Sunpaweravong P; Di Maria MV; Crawford ED
Urol Oncol; 2004; 22(1):16-9. PubMed ID: 14969798
[TBL] [Abstract][Full Text] [Related]
40. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]